Bronchiectasis is a chronic autoimmune respiratory disorder characterized by recurrent respiratory tract infections including cough and sputum production, resulting in frequent exacerbations and poor QOL. Although no treatments are currently approved, the cornerstone of the bronchiectasis drug market is antibiotics, which are typically prescribed as first-line pharmacological therapy to address underlying infections. These agents are available in multiple formulations including oral, inhaled, and IV. Separately, anti-inflammatory therapies such as inhaled and oral corticosteroids, bronchodilators (e.g., AstraZeneca’s Symbicort), and mucolytic agents (e.g., Genentech’s Pulmozyme) are used for symptomatic relief. The IL-13 and IL-5 biologics (e.g., Sanofi / Regeneron’s Dupixent, GSK’s Nucala) may also be considered in very rare, severe cases.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.